Evidence map›Paper›PMID 26884832›Full record

ArticleInternational journal of clinical and experimental pathology2015

MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1.

Rongquan He, Lihua Yang, Xiaomiao Lin, Xin Chen, Xinggu Lin, Fanglin Wei, Xiaona Liang, Yihuan Luo, Yuzhuang Wu, Tingqing Gan and 2 more

Erratum issuedAbstract readComparative Study
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Rongquan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Lihua YangDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Xiaomiao LinDepartment of Children Rehabilitation Medicine, Guangxi Maternal and Child Health Hospital Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Xin ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Xinggu LinKey Laboratory for Genomic and Personalized Medicine, Guangxi Medical University Nanning, P. R. China.
Fanglin WeiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Xiaona LiangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Yihuan LuoDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Yuzhuang WuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Tingqing GanDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Yiwu DangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMiR-30a-5p has been reported to play vital roles in the carcinogenesis and progression of various malignancies via different molecular mechanisms. However, the role and target genes of miR-30a-5p in hepatocellular carcinoma (HCC) remain still unclear. In silico analysis finds that there are complementary sequences between the 3'-untrasnlated region of astrocyte elevated gene 1 (AEG-1) and miR-30a-5p. Herein, we investigated the biological function of miR-30a-5p, as well as the potential molecular mechanism via targeting AEG-1 in HCC cells. MATERIALS AND

methodsMiR-30a-5p inhibitor, miR-30a-5p mimic, AEG-1 siRNAs, as well as their negative controls were transfected into HCC cell lines HepG2, SMMC-7221, HepB3 and SNU449. Then, the in vitro influence and mechanism of miR-30a-5p on cell viability, proliferation, caspase-3/7 activity and apoptosis were studied, as assessed by different methods, including spectrophotometry, fluorimetry, fluorescence microscopy of Hoechst 33342/propidium iodide double chromatin staining, western blot and dual luciferase reporter assay, respectively.

resultsMiR-30a-5p mimic markedly inhibited cell growth, also induced caspase-3/7 activity and apoptosis in all four HCC cell lines tested. The strongest effect was observed in HepG2 and SMMC-7721 cells. However, this effect was slightly weaker than that of AEG-1 siRNAs. Transfection of miR-30a-5p mimic led to a markedly reduced AEG-1 protein level and further dual luciferase reporter assay confirmed that AEG-1 was one of the target genes of miR-30a-5p in HCC cells.

conclusionsMiR-30a-5p may play an essential role in the cell growth and apoptosis of HCC cells, partially via targeting AEG-1.

Indexed as

ApoptosisCell Proliferation3' Untranslated RegionsBinding SitesCarcinoma, HepatocellularCaspase 3Caspase 7Cell Adhesion MoleculesCell SurvivalGene Expression Regulation, NeoplasticGenes, ReporterHep G2 CellsHumansLiver NeoplasmsMembrane ProteinsMicroRNAs3' Untranslated RegionsCASP3 protein, humanCASP7 protein, humanCaspase 3Caspase 7Cell Adhesion MoleculesMembrane ProteinsMicroRNAsMIRN30b microRNA, humanMTDH protein, humanRNA-Binding ProteinsAEG-1apoptosiscaspasecell growthhepatocellular carcinomamiR-30a-5p

Identifiers

PMID26884832
PMCPMC4730045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.